Gilead Sciences just made a big move, announcing a 7.8 billion deal to buy Arcellx. It's their biggest acquisition since 2020, signaling they're serious about moving beyond just HIV and liver disease treatments.
Arcellx shares shot up right after the news. Gilead's offering 115 per share in cash, plus another 5 per share if Arcellx hits certain sales targets. Altogether, that's about a 68 premium over Arcellx's recent average share price.
These two companies have joined forces before. Gilead's Kite Pharma and Arcellx are joining forces on a new CAR-T therapy called anito-cel-it's a mouthful, but that's what most people call it. This treatment targets people with multiple myeloma that just won't quit or doesn't react to anything else. The FDA's reviewing anito-cel as a fourth-line option, and Gilead's hoping for a decision by December 23, 2026.
